Ensuring medication ingestion without altering existing medication regimen

确保药物摄入而不改变现有的药物治疗方案

• 批准号: 10384824
• 负责人: Tony Chris Carnes
• 金额: $ 49.64万
• 依托单位: ETECTRX, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10384824
• 关键词: Accidents; Address; Adherence; Age; Alzheimer' s Disease; Assisted Living Facilities; Bulla; COVID-19 pandemic; Caregivers; Caring; Chronic Disease; Communication; Data; Dementia; Detection; Development; Disease Management; Dose; Drug Prescriptions; Early Intervention; Elderly; Encapsulated; Ensure; Environment; Event; Feedback; Frequencies; Galantamine; Generations; Grant; Health care facility; Hearing; Home; Impaired cognition; Individual; Ingestion; Intervention; Interview; Long-Term Care; Monitor; Neck; Network-based; Nursing Homes; Participant; Patients; Persons; Pharmaceutical Preparations; Phase; Radio; Reader; Regimen; Reporting; Retirement; Signal Transduction; Small Business Innovation Research Grant; Stomach; Structure; Symptoms; System; Technology; Time; aging population; base; capsule; care costs; care providers; cloud based; cost; design; donepezil; effectiveness evaluation; experience; improved; medication compliance; memory care; mobile application; monitoring device; pill; prototype; radio frequency; remote monitoring; repository; rivastigmine; sensor; signal processing; usability

PROJECT SUMMARY In the US, approximately 835,000 persons are living in assisted living facilities with more than 50 percent of those having some form of dementia or cognitive impairment. The average cost of those living in assisted living facilities is $4050 per month, with memory care increasing this cost by an average of $1250 per month. Advancements in medications such as Donepezil, Galantamine, and Rivastigmine have been shown to help manage and even reverse some dementia symptoms, but these medications are not effective unless they are taken on a regular basis. Slowing the progression of dementia can prolong the ability of persons to live independently. While the use of blister packs and pill boxes are designed to help ensure that patients are taking medications on a prescribed basis, these technologies report intent to ingest and often do not provide any feedback that can be monitored by others outside the home. Given that 53 million US citizens are already past retirement age and that 70 percent will require some form of long-term care in their lifetime, it is clear that the cost of managing this disease will continue to grow unless alternative solutions are put in place. In Phase I of the grant we propose to enhance the FDA cleared ID-Cap system by building a home-based ingestion monitoring system that can detect medication ingestions within the home instead of requiring a user to wear an ID-Cap Reader. The ID-Cap system is currently designed to detect ingestions by sending out a small radio signal from within a person's stomach when an ID-Cap is ingested. The existing system detects these signals using a lanyard-style reader. As these patients may forget to use the reader, we propose to create a new reader design that can “hear” the ingestion from across the room using improvements in antenna design and signal processing. To ensure detection if a patient takes their medication in different rooms, a mesh network of readers placed in the home can ensure that the signal is detected and forwarded to the existing cloud-based monitoring platform. In Phase I, we propose two specific aims. Aim 1 – Create a prototype wall-plug based networked reader Leveraging our experience developing the existing ID-Cap wearable reader, we will design a new generation reader that will be able to detect ingestions within a room instead of requiring the user to wear a reader. The captured signals will be forwarded across a mesh network to a base station that ensures delivery to a cloud repository so that care providers can monitor actual ingestion events and intervene if needed. Aim 2 – Evaluate effectiveness and acceptability of the new system in 3 simulated environments Using the prototyped base station and networked readers, we will evaluate the ability to detect signals in three different home configurations. This feedback will help inform installation configuration designs regarding the optimal number and placement of readers. Interviews with persons with dementia and their caregivers will inform acceptability.

项目概要 在美国，大约 835,000 人生活在辅助生活设施中，其中超过 50% 患有某种形式的痴呆症或认知障碍的人。生活在援助中的人的平均费用 生活设施费用为每月 4050 美元，记忆护理费用平均每月增加 1250 美元。 多奈哌齐、加兰他敏和卡巴拉汀等药物的进步已被证明有帮助 控制甚至逆转一些痴呆症症状，但这些药物只有在有效的情况下才会有效。 定期采取。减缓痴呆症的进展可以延长人们的生存能力 独立。虽然泡罩包装和药盒的使用旨在帮助确保患者服用 药物在规定的基础上，这些技术报告摄入意图，并且通常不提供任何 家庭以外的其他人可以监控的反馈。鉴于 5300 万美国公民已经过了 退休年龄，并且 70% 的人一生中需要某种形式的长期护理，很明显， 除非采取替代解决方案，否则控制这种疾病的成本将继续增加。 在拨款的第一阶段，我们建议通过建立一个基于家庭的 ID-Cap 系统来增强 FDA 批准的 ID-Cap 系统 摄入监测系统可以检测家中的药物摄入情况，而不需要用户 佩戴 ID 帽读取器。 ID-Cap 系统目前设计为通过发送一个小信号来检测摄入情况 当 ID-Cap 被吞下时，人胃内会发出无线电信号。现有系统检测到这些 使用挂绳式阅读器发出信号。由于这些患者可能会忘记使用阅读器，我们建议创建一个 新的阅读器设计，可以通过天线设计的改进“听到”整个房间的摄入情况 和信号处理。为了确保患者在不同房间服药时能够被检测到，网状网络 放置在家里的读卡器可以确保信号被检测到并转发到现有的基于云的 监控平台。在第一阶段，我们提出了两个具体目标。 目标 1 – 创建一个基于壁插式网络阅读器的原型 利用我们开发现有 ID-Cap 可穿戴读卡器的经验，我们将设计新一代 阅读器将能够检测房间内的摄入情况，而不需要用户佩戴阅读器。这 捕获的信号将通过网状网络转发到基站，确保传送到云端 存储库，以便护理人员可以监控实际的摄入事件并在需要时进行干预。 目标 2 – 在 3 个模拟环境中评估新系统的有效性和可接受性 使用原型基站和联网阅读器，我们将评估在三个方面检测信号的能力 不同的家居配置。此反馈将有助于告知安装配置设计有关 读者的最佳数量和位置。与痴呆症患者及其护理人员的访谈将告知 可接受性。